ArticleFrontiers in pharmacology2022

Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease.

Xueliang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.